Literature DB >> 33168964

Genetic testing in dementia - utility and clinical strategies.

Carolin A M Koriath1, Joanna Kenny2, Natalie S Ryan3,4, Jonathan D Rohrer3, Jonathan M Schott3, Henry Houlden5, Nick C Fox3,4, Sarah J Tabrizi6, Simon Mead7.   

Abstract

Techniques for clinical genetic testing in dementia disorders have advanced rapidly but remain to be more widely implemented in practice. A positive genetic test offers a precise molecular diagnosis, can help members of an affected family to determine personal risk, provides a basis for reproductive choices and can offer options for clinical trials. The likelihood of identifying a specific genetic cause of dementia depends on the clinical condition, the age at onset and family history. Attempts to match phenotypes to single genes are mostly inadvisable owing to clinical overlap between the dementias, genetic heterogeneity, pleiotropy and concurrent mutations. Currently, the appropriate genetic test in most cases of dementia is a next-generation sequencing gene panel, though some conditions necessitate specific types of test such as repeat expansion testing. Whole-exome and whole-genome sequencing are becoming financially feasible but raise or exacerbate complex issues such as variants of uncertain significance, secondary findings and the potential for re-analysis in light of new information. However, the capacity for data analysis and counselling is already restricting the provision of genetic testing. Patients and their relatives need to be given reliable information to enable them to make informed choices about tests, treatments and data sharing; the ability of patients with dementia to make decisions must be considered when providing this information.

Entities:  

Mesh:

Year:  2020        PMID: 33168964     DOI: 10.1038/s41582-020-00416-1

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  137 in total

1.  Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Reisa A Sperling; Paul S Aisen; Laurel A Beckett; David A Bennett; Suzanne Craft; Anne M Fagan; Takeshi Iwatsubo; Clifford R Jack; Jeffrey Kaye; Thomas J Montine; Denise C Park; Eric M Reiman; Christopher C Rowe; Eric Siemers; Yaakov Stern; Kristine Yaffe; Maria C Carrillo; Bill Thies; Marcelle Morrison-Bogorad; Molly V Wagster; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

Review 2.  Vascular Cognitive Impairment.

Authors:  Martin Dichgans; Didier Leys
Journal:  Circ Res       Date:  2017-02-03       Impact factor: 17.367

3.  Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis.

Authors:  K Abigail Andrews; Chris Frost; Marc Modat; M Jorge Cardoso; Chris C Rowe; Victor Villemagne; Nick C Fox; Sebastien Ourselin; Jonathan M Schott
Journal:  Neurobiol Aging       Date:  2015-10-22       Impact factor: 4.673

4.  The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model.

Authors:  Randall J Bateman; Tammie L Benzinger; Scott Berry; David B Clifford; Cynthia Duggan; Anne M Fagan; Kathleen Fanning; Martin R Farlow; Jason Hassenstab; Eric M McDade; Susan Mills; Katrina Paumier; Melanie Quintana; Stephen P Salloway; Anna Santacruz; Lon S Schneider; Guoqiao Wang; Chengjie Xiong
Journal:  Alzheimers Dement       Date:  2016-08-29       Impact factor: 21.566

Review 5.  Evaluation of Suspected Dementia.

Authors:  Nathan Falk; Ariel Cole; T Jason Meredith
Journal:  Am Fam Physician       Date:  2018-03-15       Impact factor: 3.292

6.  Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis.

Authors:  Sarah J Tabrizi; Rachael I Scahill; Alexandra Durr; Raymund Ac Roos; Blair R Leavitt; Rebecca Jones; G Bernhard Landwehrmeyer; Nick C Fox; Hans Johnson; Stephen L Hicks; Christopher Kennard; David Craufurd; Chris Frost; Douglas R Langbehn; Ralf Reilmann; Julie C Stout
Journal:  Lancet Neurol       Date:  2010-12-02       Impact factor: 44.182

Review 7.  Ageing as a risk factor for neurodegenerative disease.

Authors:  Yujun Hou; Xiuli Dan; Mansi Babbar; Yong Wei; Steen G Hasselbalch; Deborah L Croteau; Vilhelm A Bohr
Journal:  Nat Rev Neurol       Date:  2019-09-09       Impact factor: 42.937

Review 8.  Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease.

Authors:  Sarah J Tabrizi; Rhia Ghosh; Blair R Leavitt
Journal:  Neuron       Date:  2019-03-06       Impact factor: 17.173

9.  Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk.

Authors:  Iris E Jansen; Jeanne E Savage; Stephan Ripke; Ole A Andreassen; Danielle Posthuma; Kyoko Watanabe; Julien Bryois; Dylan M Williams; Stacy Steinberg; Julia Sealock; Ida K Karlsson; Sara Hägg; Lavinia Athanasiu; Nicola Voyle; Petroula Proitsi; Aree Witoelar; Sven Stringer; Dag Aarsland; Ina S Almdahl; Fred Andersen; Sverre Bergh; Francesco Bettella; Sigurbjorn Bjornsson; Anne Brækhus; Geir Bråthen; Christiaan de Leeuw; Rahul S Desikan; Srdjan Djurovic; Logan Dumitrescu; Tormod Fladby; Timothy J Hohman; Palmi V Jonsson; Steven J Kiddle; Arvid Rongve; Ingvild Saltvedt; Sigrid B Sando; Geir Selbæk; Maryam Shoai; Nathan G Skene; Jon Snaedal; Eystein Stordal; Ingun D Ulstein; Yunpeng Wang; Linda R White; John Hardy; Jens Hjerling-Leffler; Patrick F Sullivan; Wiesje M van der Flier; Richard Dobson; Lea K Davis; Hreinn Stefansson; Kari Stefansson; Nancy L Pedersen
Journal:  Nat Genet       Date:  2019-01-07       Impact factor: 38.330

10.  The clinical utility of gene testing for Alzheimer's disease.

Authors:  Emily R Atkins; Peter K Panegyres
Journal:  Neurol Int       Date:  2011-04-06
View more
  7 in total

1.  The Clinical Use of Alzheimer's Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer's Disease Consortium Survey.

Authors:  Camilla Caprioglio; Valentina Garibotto; Frank Jessen; Lutz Frölich; Gilles Allali; Frédéric Assal; Giovanni B Frisoni; Daniele Altomare
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

Review 2.  Rapidly Progressive Dementia.

Authors:  Gregory S Day
Journal:  Continuum (Minneap Minn)       Date:  2022-06-01

3.  Dementia and Major Neurocognitive Disorders: Some Lessons Learned One Century after the first Alois Alzheimer's Clinical Notes.

Authors:  Donatella Rita Petretto; Gian Pietro Carrogu; Luca Gaviano; Lorenzo Pili; Roberto Pili
Journal:  Geriatrics (Basel)       Date:  2021-01-11

4.  Editorial: Next Generation Sequencing (NGS) for Rare Diseases Diagnosis.

Authors:  Xiu-An Yang
Journal:  Front Genet       Date:  2021-12-23       Impact factor: 4.599

5.  Differences and similarities between familial and sporadic frontotemporal dementia: An Italian single-center cohort study.

Authors:  Alberto Benussi; Ilenia Libri; Enrico Premi; Antonella Alberici; Valentina Cantoni; Yasmine Gadola; Jasmine Rivolta; Marta Pengo; Stefano Gazzina; Vince D Calhoun; Roberto Gasparotti; Henrik Zetterberg; Nicholas J Ashton; Kaj Blennow; Alessandro Padovani; Barbara Borroni
Journal:  Alzheimers Dement (N Y)       Date:  2022-07-25

6.  Editorial: Current advances in genetic dementia and aging.

Authors:  Yuzhen Xu; Daojun Hong; Ulises Gomez-Pinedo; Jun Liu; Jun Xu
Journal:  Front Aging Neurosci       Date:  2022-09-14       Impact factor: 5.702

7.  Estimation of the number of inherited prion disease mutation carriers in the UK.

Authors:  Rosie Corbie; Tracy Campbell; Lee Darwent; Peter Rudge; John Collinge; Simon Mead
Journal:  Eur J Hum Genet       Date:  2022-06-27       Impact factor: 5.351

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.